CNBCLean R·
This cancer drug stock could double as its treatment hits the market, JPMorgan says
The investment bank initiated coverage with an overweight rating.
Read at CNBC →
New York TimesLean L
The investment bank initiated coverage with an overweight rating.
<iframe src="https://statesidedaily.com/embed/cluster/37cfd5844d7a25d6a7df52f046bcd7aef1b1e289" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="This cancer drug stock could double as its treatment hits the market, JPMorgan says"></iframe>